Induction Toripalimab and Chemotherapy in Locally Advanced Cervical Cancer

Recruiting now · Phase 1/Phase 2

Conditions studied: Cervical Cancer, Induction Chemotherapy, Immunotherapy

In brief

To explore the efficacy of incorporating neoadjuvant immunotherapy into neoadjuvant chemotherapy in locally advanced cervical cancer patients with high risk of recurrence.

Key facts

Study ID

NCT06093438

Run by

Tianjin Medical University Cancer Institute and Hospital

People needed

20

Starts

2023-11-01

Expected to finish

2026-07-01

Last updated by the study team

2025-03-11

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Untreated locally advanced cervical cancer patients with clear pathological diagnosis
• 2019 FIGO stage IIIB-IVA. For patients with stage IIIC disease, the short diameter of their metastatic lymph nodes should ≥1.5cm
• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
• Life expectancy > 6 months
• Able to tolerate concurrent chemoradiotherapy assessed by researches
• No obvious active bleeding;
• Adequate hematological, renal and hepatic functions:
• No concomitant malignancies
• Female subjects of childbearing potential should have a negative pregnancy test and must take effective and reliable contraceptive measures during the clinical trial period;
• Voluntarily-signed informed consent.

You may not qualify if…

• Concomitant other malignancies;
• Patients with metastatic or recurrent disease;
• Patients received any form of treatment before enrollment;
• Severe concomitant chronic diseases (diabetes, hypertension, etc.) or acute infections;
• Impaired hematological, renal or hepatic functions:
• Hemoglobin < 9.0 g/dl
• Neutrophils < 2000 cells/μl; Leukocytes < 4 × 109/L
• Platelets > 100 × 109/L
• Serum ALT/AST > 2.5×UNL
• Serum Total bilirubin > 1.5× UNL
• g. Serum urea nitrogen (BUN) > 1.5 × upper normal limit (UNL) h. Serum creatinine (Cr) > 1.5 × upper normal limit (UNL)
• Patients with obvious arrhythmia, myocardial ischemia, severe atrioventricular block, cardiac insufficiency or severe heart valve disease;
• Patients with uncontrolled mental diseases;
• Pregnant or lactating woman;
• Participating in other clinical trials;
• Anyone considered not suitable for enrollment by principal investigator;

Where it is running

• Tianjin Medical University Cancer Institute & Hospital — Tianjin, Tianjin Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.